This website is intended for healthcare professionals outside of the US only.

Pombiliti® ▼ (cipaglucosidase alfa) UK Prescribing Information Opfolda® (miglustat) UK Prescribing Information Pombiliti European (EMA) SmPC Opfolda European (EMA) SmPC Report adverse event
Amicus Therapeutics

Welcome toPompe Exchange

A new peer-to-peer educational programme, funded by Amicus Therapeutics and co-developed with a Global Organising Committee of Pompe expert clinicians.

FIND OUT MORE

Pompe Exchange webinar
25th November 2025
12:30 GMT / 13:30 CET

Featuring NEW DATA from the 4-year PROPEL open-label extension, real-world
evidence in late-onset Pompe disease (LOPD), and discussions from
our Pompe expert clinicians.

This website is intended for healthcare professionals outside of the US only.

Adverse events should be reported

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported. For the UK (including Northern Ireland), reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Amicus on 08082346864 or via email to drugsafety@amicusrx.com

Copyright © 2026 Amicus Therapeutics, Inc. All rights reserved

PP-AT-ABP-0009-1025-2 | January 2026

Cookie Statement Cookie Policy Terms of Use Privacy Policy

You are about to be redirected to an external site

Amicus are not responsible for the content of external sites

Go Back
Continue

Are you a licensed Healthcare Professional?

Yes No